Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

10 For 2020: Regulatory Trends To Watch In China

Jan 05 2020

• By Brian Yang

Pink Sheet Perspectives 2019 to 2020 — Intense Activity Marks China's Regulatory Year

Related Content

Vaccine Maker Bankruptcy Shows Regulatory Perils Of Business In China

Nov 14 2019

China Alzheimer's Approval Raises Hope But Also Questions

Nov 05 2019

China's New Pharma Law Leaves Key Questions Unanswered

Sep 05 2019

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

Dec 12 2019

Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?

Nov 29 2019

Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

Oct 21 2019

China Forced Tech Transfer Still A Problem, EU Firms Say

May 23 2019

GSK Divests China Suzhou Site, Antiviral Rights To Fosun

Jul 12 2019

Loss And Gain: Trade War Halves China Biotech VC Funding To US, But Asian Countries May Benefit

Jul 17 2019

R&D Executives Seek China Role In Clinical Development

Mar 14 2019

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Shanghai Henlius Biotech Co. Ltd.

AstraZeneca PLC

Sanofi

Ascletis Pharma, Inc.

GSK plc

Additional Topics

China Asia Pacific Regulation Approvals Neurology BioPharmaceutical

More from China

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window